Recent changes in the industry include changes at the top at Prothena and 180 Life Sciences, plus Cantargia acquires chief business officer from Ultimovacs.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Paying €90m upfront for rights to generalized pustular psoriasis drug.
Recent moves in the industry include C-suite changes at Essential Pharma, plus Kyverna Therapeutics gets new chief financial officer from Alector.
Joshi joins the parent company of Citeline, which houses flagship publications Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.
Teva VP-global R&D and chief medical officer Eric Hughes talked to Scrip about building the company’s innovative pipeline in its growth-acceleration phase.
The biotech announced positive Phase II data for the drug combined with AbbVie/Roche’s Venclexta and BMS’s Vidaza in relapsed/refractory acute myeloid leukemia.
Big pharma is increasingly looking east to restock its pipelines, a process that is helping to forge a new generation of mid-sized R&D-based companies in China and is reflected in their stock price performance.
Nanoscope’s experimental gene therapy, MCO-010, is designed to target the broader retinitis pigmentosa population, regardless of the underlying gene mutation, with a completed US regulatory submission expected in early 2026.
